Açar Elif, Köylüce Serpil, Şeker Serhat, Bozkurt Yilmaz Hatice Eylül, Aktaş Yapici Elif, Arslan Bahar, Paçaci Çetin Gülden, Türk Murat, Yilmaz İnsu
Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye.
Tuberk Toraks. 2025 Mar;73(1):52-59. doi: 10.5578/tt.2025011058.
The negative effects of eosinophilic severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) on quality of life are well known. The present study aimed to evaluate the impact of mepolizumab treatment on the quality of life of patients diagnosed with eosinophilic severe asthma and CRSwNP.
Patients with CRSwNP and eosinophilic severe asthma who had been receiving mepolizumab 100 mg/month for at least six months as treatment were eligible for the study. Patients were assessed using quality of life and disease control questionnaires for both diseases before and during the sixth month of treatment.
Forty-nine patients were included in the present study. Compared to the pre-treatment period, there was significant clinical improvement in quality of life for both rhinitis and asthma following mepolizumab treatment. The changes before and after the treatment were found as follows: Rhinitis Quality of Life Scale [44 (23-72); 25 (6-57); p< 0.001], Nasal Congestion Symptom Assessment Scale [13.0 (8-20); 9.0 (0-20); p< 0.001], Sino-Nasal Outcomes Test-22 (63.16 ± 17.9; 44.16 ± 21.33; p< 0.001), Asthma Quality of Life Questionnaire (111.06 ± 25.17; 142.67 ± 28.04; p< 0.001), Asthma Control Test [16 (6-21); 22 (14-25); p< 0.001]. Before mepolizumab treatment, 20 patients defined that CRSwNP and 29 patients defined that asthma affected their quality of life primarily. After six months of mepolizumab treatment, 38 patients defined that CRSwNP and 11 patients defined that asthma affected their quality of life primarily.
Our results showed that mepolizumab is an effective treatment option for eosinophilic severe asthma and CRSwNP in patients having both diseases. Before mepolizumab, most patients' quality of life was affected by asthma symptoms, but this changed, and their quality of life began to be affected primarily by CRSwNP symptoms. This suggests that mepolizumab treatment is more effective in suppressing asthma symptoms than suppressing nasal polyp symptoms.
嗜酸性粒细胞性重度哮喘和伴鼻息肉的慢性鼻-鼻窦炎（CRSwNP）对生活质量的负面影响是众所周知的。本研究旨在评估美泊利珠单抗治疗对诊断为嗜酸性粒细胞性重度哮喘和CRSwNP患者生活质量的影响。
接受美泊利珠单抗100mg/月治疗至少六个月的CRSwNP和嗜酸性粒细胞性重度哮喘患者符合本研究条件。在治疗的第六个月之前和期间，使用两种疾病的生活质量和疾病控制问卷对患者进行评估。
本研究纳入了49例患者。与治疗前相比，美泊利珠单抗治疗后鼻炎和哮喘的生活质量均有显著临床改善。治疗前后的变化如下：鼻炎生活质量量表[44（23 - 72）；25（6 - 57）；p < 0.001]，鼻充血症状评估量表[13.0（8 - 20）；9.0（0 - 20）；p < 0.001]，鼻窦结局测试 - 22（63.16 ± 17.9；44.16 ± 21.33；p < 0.001），哮喘生活质量问卷（111.06 ± 25.17；142.67 ± 28.04；p < 0.001），哮喘控制测试[16（6 - 21）；22（14 - 25）；p < 0.001]。在美泊利珠单抗治疗前，20例患者认为CRSwNP，29例患者认为哮喘主要影响他们的生活质量。美泊利珠单抗治疗六个月后，38例患者认为CRSwNP，11例患者认为哮喘主要影响他们的生活质量。
我们的结果表明，美泊利珠单抗是患有这两种疾病的嗜酸性粒细胞性重度哮喘和CRSwNP患者的有效治疗选择。在使用美泊利珠单抗之前，大多数患者的生活质量受哮喘症状影响，但这种情况发生了变化，他们的生活质量开始主要受CRSwNP症状影响。这表明美泊利珠单抗治疗在抑制哮喘症状方面比抑制鼻息肉症状更有效。
